Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.320 Biomarker group CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.320 AlteredExpression group BEFREE RT-PCR products with the predicted size and sequence of PTI-1 are detected in RNAs from cell lines of human prostate, breast, and colon carcinomas. 8988032 1997
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.320 AlteredExpression group BEFREE By using a pair of primers recognizing a 280-bp region within the 630-bp 5' PTI-1 sequence, reverse transcription-PCR detects PTI-1 expression in patient-derived prostate carcinomas but not in normal prostate or benign hypertrophic prostate tissue. 7542776 1995
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.300 Biomarker disease CTD_human Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. 19424620 2009
CUI: C0038356
Disease: Stomach Neoplasms
Stomach Neoplasms
0.300 Biomarker group CTD_human Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. 19424620 2009
CUI: C1708349
Disease: Hereditary Diffuse Gastric Cancer
Hereditary Diffuse Gastric Cancer
0.300 Biomarker disease CTD_human Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. 19424620 2009
CUI: C0024667
Disease: Animal Mammary Neoplasms
Animal Mammary Neoplasms
0.300 Biomarker phenotype CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental
0.300 Biomarker phenotype CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0205696
Disease: Anaplastic carcinoma
Anaplastic carcinoma
0.300 Biomarker disease CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0205697
Disease: Carcinoma, Spindle-Cell
Carcinoma, Spindle-Cell
0.300 Biomarker disease CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0205698
Disease: Undifferentiated carcinoma
Undifferentiated carcinoma
0.300 Biomarker disease CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0205699
Disease: Carcinomatosis
Carcinomatosis
0.300 Biomarker phenotype CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C1257925
Disease: Mammary Carcinoma, Animal
Mammary Carcinoma, Animal
0.300 Biomarker disease CTD_human cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 12376462 2002
CUI: C0409959
Disease: Osteoarthritis, Knee
Osteoarthritis, Knee
0.200 Biomarker disease RGD Proteomic analysis of rat cartilage: the identification of differentially expressed proteins in the early stages of osteoarthritis. 25435813 2014
Red cell distribution width determination
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
RDW - Red blood cell distribution width result
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE Reciprocal relationship of differential expression between EEF1A isoforms observed in multiple cancer types indicates opposing roles in cancer and needs further investigation. 29342219 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 Biomarker group BEFREE Encoded by EEF1A1, the eukaryotic translation elongation factor eEF1α1 strongly promotes the heat shock response, which protects cancer cells from proteotoxic stress, following for instance oxidative stress, hypoxia or aneuploidy. 30224719 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.070 Biomarker group BEFREE Encoded by EEF1A1, the eukaryotic translation elongation factor eEF1α1 strongly promotes the heat shock response, which protects cancer cells from proteotoxic stress, following for instance oxidative stress, hypoxia or aneuploidy. 30224719 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.070 AlteredExpression group BEFREE Reciprocal relationship of differential expression between EEF1A isoforms observed in multiple cancer types indicates opposing roles in cancer and needs further investigation. 29342219 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML. 28678185 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.070 AlteredExpression group BEFREE Given that deregulated mRNA translation is a frequent feature of cancer and that eEF1A1 is highly expressed in many human tumours, these findings present new possibilities for the therapeutic targeting of EZH2 in AML. 28678185 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 Biomarker group BEFREE These suggested eEF1A1 as a molecular marker to predict the selectivity and efficiency of 5-ALA based PDT in cancer therapy. 27150264 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.070 Biomarker group BEFREE These suggested eEF1A1 as a molecular marker to predict the selectivity and efficiency of 5-ALA based PDT in cancer therapy. 27150264 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE Nannocystin A (1) displayed differential activity across various cancer cell lines and EEF1A1 expression levels appear to be the main differentiating factor. 26179970 2015